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Few risk scores are available for predicting mortality in chronic kidney disease (CKD) pa-
tients undergoing predialysis nephrology care. Here, we developed a risk score using pre-
dialysis nephrology practice data to predict 1-year mortality following the initiation of
haemodialysis (HD) for CKD patients.
Methods
This was a multicenter cohort study involving CKD patients who started HD between April
2006 and March 2011 at 21 institutions with nephrology care services. Patients who had not
received predialysis nephrology care at an estimated glomerular filtration rate (eGFR) of ap-
proximately 10 mL/min per 1.73 m2 were excluded. Twenty-nine candidate predictors were
selected, and the final model for 1-year mortality was developed via multivariate logistic re-
gression and was internally validated by a bootstrapping technique.
Results
A total of 688 patients were enrolled, and 62 (9.0%) patients died within one year of HD ini-
tiation. The following variables were retained in the final model: eGFR, serum albumin,
calcium, Charlson Comorbidity Index excluding diabetes and renal disease (modified
CCI), performance status (PS), and usage of erythropoiesis-stimulating agent (ESA).
Their β-coefficients were transformed into integer scores: three points were assigned to
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modified CCI3 and PS 3–4; two to calcium>8.5 mg/dL, modified CCI 1–2, and no use of
ESA; and one to albumin<3.5 g/dL, eGFR>7 mL/min per 1.73 m2, and PS 1–2. Predicted
1-year mortality risk was 2.5% (score 0–4), 5.5% (score 5–6), 15.2% (score 7–8), and
28.9% (score 9–12). The area under the receiver operating characteristic curve was 0.83
(95% confidence interval, 0.79–0.89).
Conclusions
We developed a simple 6-item risk score predicting 1-year mortality after the initiation of HD
that might help nephrologists make a shared decision with patients and families regarding
the initiation of HD.
Introduction
Although intervention by nephrologists to chronic kidney disease (CKD) patients before initia-
tion of haemodialysis (HD) is increasing, these patients still have poor outcome. Therefore, it is
important for the nephrologists to practice shared decision making with CKD patients and
their families regarding the initiation of HD based on informed estimates of early mortality
risk. Although several risk scores based on the clinical parameters at the initiation of HD have
been previously reported, the risk score to predict mortality risk after initiation of dialysis treat-
ment among CKD patients under predialysis nephrology care is scarce.
Couchoud et al. developed a simple clinical score predicting early mortality in CKD patients
starting HD [1]. Although this score was a simple integer score, this study only enrolled elderly
patients and included those with unplanned initiation of HD. In addition, the estimated glo-
merular filtration rate (eGFR) at the initiation of HD was not incorporated into this score, de-
spite being a strong prognostic factor [2] that varies by country and should therefore be
considered in mortality prediction. For example, the proportion of patients with eGFR>10
mL/min at the initiation of HD was 11% in Japan [3] and 36% in USA [4]. van Diepen et al. de-
veloped a predictive model for incident dialysis patients with consideration of residual GFR as
a candidate predictor, whereas this model was only applicable to diabetic dialysis patients and
difficult to calculate [5]. Therefore, a simple risk score using daily practice data is necessary for
nephrologists to predict mortality of CKD patients after initiation of dialysis treatment without
restriction of patients’ age or underlying diseases.
Using multicenter clinical data measured immediately before the initiation of HD, we devel-




We conducted a retrospective cohort study of patients starting HD at 19 tertiary care institu-
tions and two clinics. This study was approved by the ethics committee of the Okayama Uni-
versity Graduate School of Medicine, Dentistry and Pharmaceutical Sciences (authorization
number: 538) and registered with the University Hospital Medical Information Network Clini-
cal Trials Registry (UMIN000007862). Informed consent from participants was ruled unneces-
sary because we retrospectively analyzed data routinely collected from all patients and we
analyzed the data anonymously.
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Patients
In this study, renal function was evaluated by eGFR using the following equation developed
for Japanese patients: eGFR (mL/min per 1.73 m2) = 194 × Serum creatinine-1.094 × Age-0.287
(× 0.739 if female) [6]. The inclusion criteria for this study were as follows: patients who
started HD between April 2006 and March 2011; and eGFR during predialysis nephrology
care could be confirmed in medical records and were shown to have reached to 10 mL/min
per 1.73 m2 to eliminate patients with unplanned HD initiation. The criteria for exclusion
from this study were as follows: those whose eGFR could not be confirmed during predialysis
nephrology care because of unplanned initiation or failure to measure; those who started HD
before their eGFR had reached to 10 mL/min per 1.73 m2; withdrawal of HD treatment with-
in one year; and under 20 years old.
Data Collection and Processing
Data at the initiation of HD were collected from medical records, including demographic infor-
mation, underlying renal disease, clinical symptoms, laboratory data, Charlson Comorbidity
Index (CCI) [7], performance status categorised using scales of the World Health Organization
performance status except category 5 (death) [8], and treatment status.
Outcome Measures & Candidate Predictors
The primary outcome measure was all-cause mortality within one year of starting HD. Candi-
date predictors were selected according to a literature review and clinical expertise. Candidate
predictors need to be biologically plausible and available in the majority of nephrology practice
settings. We therefore selected information on 29 variables, including patient demographics
(age, gender, primary renal disease [diabetic nephropathy or other renal disease], and body
mass index), laboratory data (eGFR, haemoglobin, urea nitrogen, serum potassium, calcium,
phosphorus, albumin, and C-reactive protein), CCI, performance status, symptoms related to
uremia (fatigue, edema, pulmonary edema, nausea, dysorexia, diarrhea, constipation, other di-
gestive symptoms, hypertension, peripheral neuropathy, psychiatric disorder, haemorrhagic
diathesis, diabetic retinopathy, and itch), and nephrologists’ treatments (erythropoiesis-stimu-
lating agent [ESA]) (Table 1). Uremic symptoms are diagnosed by attending physician. In
Japan, almost all patients initiating HD hand in the certificate of attending physician for mak-
ing use of public support. This certificate includes the following items: chest X-ray, fundus fea-
ture, peripheral neuropathy, digestive symptom, psychiatric disorder, severe hypertension, and
so on. We collected the data about uremic symptoms from these certificate and medical rec-
ords. We modified CCI by excluding the items related to diabetes and renal disease in this
study for the following reasons: all patients have “moderate or severe renal disease”; and diabe-
tes is included in another variable, that is, primary renal disease.
Data Description & Handling Missing Data
Descriptive statistics on candidate predictors and the outcome variable are presented as median
or percentage as appropriate.
At least one variable was missing in 183 patients (26.6%). As complete case analysis leads to
loss of power and biased results, a multiple imputation approach was utilized to derive predic-
tions for the missing values [9]. Whereas simulation studies have shown that required number
of imputations can be as three for data with 20% of missing entries [10], the largest percentage
of missing among candidate predictors was 6.7% (46 of 688 patients) for C-reactive protein,
and thus five repeated imputations would be considered a conservative choice. Five
One-year Mortality Score for Patients Initiating HD
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Table 1. Candidate predictors and outcome variables.
Number missing Analysis cohort (n = 688) Survived (n = 626) Died (n = 62)
Age, year 0 69 (59–77) 69 (59–76) 73 (65–78)
Female gender, % 0 33.4 33.5 32.3
Body mass index 23 22.7 (20.6–25.4) 23.0 (20.7–25.5) 21.5 (19.6–23.9)
Diabetic nephropathy, % 0 42.6 43.8 30.7
eGFR, mL/min per 1.73 m2 0 5.43 (4.37–6.71) 5.38 (4.36–6.55) 6.40 (4.89–7.89)
Urea nitrogen, mg/dL 2 86.2 (69.5–106.8) 86.1 (70.0–106.0) 90.1 (67.7–116.1)
Haemoglobin, g/dL 1 8.7 (7.7–9.7) 8.7 (7.7–9.7) 8.4 (7.4–9.5)
Serum albumin, g/dL 34 3.2 (2.8–3.6) 3.3 (2.9–3.6) 3.0 (2.6–3.4)
Serum potassium, mg/dL 4 4.5 (4.0–5.0) 4.5 (4.1–5.0) 4.7 (3.7–5.4)
Serum calcium, mg/dL 12 7.9 (7.3–8.4) 7.9 (7.3–8.4) 7.8 (7.5–8.6)
Serum phosphorus, mg/dL 13 5.7 (4.8–6.7) 5.7 (4.8–6.8) 5.4 (4.8–6.4)
C-reactive protein, mg/dL 46 0.21 (0.07–0.99) 0.20 (0.06–0.80) 0.99 (0.18–3.07)
Modiﬁed Charlson Comorbidity Indexa 22
0, % 45.6 48.9 11.9
1–2, % 42.5 40.7 61.0
3, % 11.9 10.4 27.1
Performance status 5
0, % 14.7 15.8 3.2
1, % 40.1 41.9 22.6
2, % 21.2 22.0 12.9
3, % 16.0 13.6 40.3
4, % 7.3 0.6 19.3
Fatigue, % 11 73.0 72.5 78.0
Edema, % 2 65.5 65.6 63.9
Pulmonary edema, % 5 23.9 23.6 26.2
Nausea, % 9 36.4 35.6 44.2
Dysorexia, % 8 61.9 61.1 70.5
Diarrhea, % 7 4.9 4.7 6.6
Constipation, % 14 4.9 5.1 3.3
Other digestive symptom, % 9 1.3 1.0 5.0
CNS manifestation, % 4 3.1 2.4 9.8
Peripheral nerve abnormalities, % 8 12.4 12.3 13.1
Itch, % 19 10.0 10.5 4.9
Haemorrhagic diathesis, % 3 2.3 2.1 4.9
Hypertension, % 4 60.7 62.1 45.9
Diabetic retinopathy, % 45 35.3 36.1 26.8
ESA use, % 6 85.8 87.5 67.7
Continuous variables represented as median with interquartile range in parentheses.
eGFR, estimated glomerular ﬁltration rate; CNS, central nervous system; ESA, erythropoiesis-stimulating agent
aItems related to diabetes and renal disease were excluded from the original Charlson Comorbidity Index in the present study.
doi:10.1371/journal.pone.0129180.t001
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imputations were performed using multiple imputations with chained equations [10, 11]. Pro-
cess of the multiple imputation and derivation of the prediction rule was shown as Fig 1.
Derivation Phase
The association of candidate predictors with 1-year mortality was modeled with multivariate
logistic regression. Continuous predictor variables were categorized as appropriate with refer-
ence to β-coefficients of bivariate logistic regression models. Selection of predictors was based
Fig 1. Process of the multiple imputation and derivation of the prediction rule. (1) Five multiply imputed
datasets were created using original data. (2) Backward elimination was separately applied to each of the five
imputed datasets, resulting in five sets of selected predictors. (3) Predictors that were selected in all of the
five data sets were chosen as the final set of selected predictors, with exclusion of some predictors based on
balance between number of candidate predictors with number of outcomes (deaths) and discussion
according to clinical relevance. (4) The logistic regression with the selected six predictors was separately
applied to each of the five imputed data sets, giving five sets of β-coefficients of the six predictors. (5) To
avoid overfitting, each of five sets of β-coefficients of the six predictors were shrunken using heuristic
shrinkage factor. Then, the mean for each of the five estimates for β-coefficients of the final model were taken
and variances of the five estimates were pooled according to Rubin’s rules. (6) The shrunken β-coefficients of
the predictors in the final model divided by two-fifths of the two small β-coefficients in the model and rounded
up to the nearest integer to give a simple point score.
doi:10.1371/journal.pone.0129180.g001
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on backward elimination of variable with P-value>0.157, which is equivalent to the use of the
Akaike information criterion (AIC) for model selection [12].
A majority method was selected to obtain a final set of selected predictors [9]. First, back-
ward elimination was separately applied to each of the five imputed data sets (Fig 1, (2)), result-
ing in five sets of selected predictors. Second, predictors that were selected in all of the five data
sets were chosen as the final set of selected predictors (Fig 1, (3)), with exclusion of some pre-
dictors based on balance between number of candidate predictors with number of outcomes
(deaths) and discussion according to clinical relevance. Third, the logistic regression with the
selected predictors was separately applied to each of the five imputed data sets (Fig 1, (4)). Fi-
nally, the mean for each of the five estimates for β-coefficients of the final model were taken
and variances of the five estimates were pooled according to Rubin’s rules (Fig 1, (5)) [10, 13].
In a derivation phase, overfitting should be adjusted for, especially when a large number of
candidate predictors compared to number of outcomes (deaths) was considered or automated
variable selection such as backward elimination was used [14]. To account for this, the β-coeffi-
cients derived from each of the imputed data sets were multiplied by a heuristic shrinkage fac-
tor, as follows:
ðw2model  dfÞ=w2model
where χ2model denotes the model chi-square and df denotes the degree of freedom (Fig 1, (5)).
This approach is a post hoc method to adjust β-coefﬁcients of the predictors for overﬁtting and
avoids extreme predictions when applied to new patients [11, 15]. The shrunken β-coefﬁcients
of the predictors in the ﬁnal model divided by two-ﬁfths of the two small β-coefﬁcients in the
model and rounded up to the nearest integer to give a simple point score (Fig 1, (6)).
Validation Phase
The validation was performed using single imputed data among the five imputed data generat-
ed in the derivation phase, as the single imputation validation is a temporary stand-in for the
multiple imputation fit [16]. To validate the final model, we selected a bootstrapping technique
with 2000 resamples that, in contrast to the data-splitting technique, preserves the sample size
and leads to more precision and power [17]. This technique estimates the likely performance
of the prediction rule on a new sample of patients from the same patient population. The ability
to discriminate between patients with and without 1-year mortality was assessed by the area
under the receiver operating characteristic (ROC) curve. The agreement between predicted
1-year mortality based on the rule and the observed mortality risk was assessed with a calibra-
tion plot [15, 17].
Total scores were calculated by adding the scores for each final predictor. Patients were then
categorized into total score categories and their observed risks of 1-year mortality
were compared.
All statistical analyses were performed using Stata version 11.2 (Stata Corp., College Station,
TX, USA) and R software (http://www.R-project.org).
Results
Description of Candidate Predictors and Outcome Variable
A total of 688 patients enrolled in this study. The candidate predictors and the outcome vari-
ables are described in Table 1. Median age of patients was 69 years, 230 patients (33.4%) were
female, and 42.6% (293 of 688 patients) had diabetic nephropathy as an underlying disease.
Median HD-free interval from eGFR of 10 mL/min per 1.73 m2 was 196 days, median eGFR at
One-year Mortality Score for Patients Initiating HD
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initiation of HD was 5.43 mL/min per 1.73 m2, and 85.8% (585 of 682 patients) were adminis-
tered ESA before initiation of HD. Only 11.6% (79 of 684 patients) had a modified CCI of 0
points, and 85.3% (583 of 683 patients) had deteriorated activities of daily living defined as per-
formance status. A total of 62 patients (9.0%) died within one year of starting HD.
Derivation
Multivariable logistic regression analysis with backward elimination procedure showed that
the following variables were retained in all of the five imputed dataset: eGFR>7 mL/min per
1.73 m2, serum albumin<3.5 g/dL, calcium>8.5 mg/dL, modified CCI1 points (higher risk
for3 points), performance status1 points (higher risk for 3–4 points), body mass index>18,
pulmonary edema, and ESA use (Table 2). Among the eight candidate predictors, two were ex-
cluded: body mass index (based on discussion that body height and body weight will be unlike-
ly to be obtained among patients with decreased performance status), pulmonary edema
(based on discussion that it was anti-intuitive for future use that odds ratio of presence of pul-
monary edema for death was<1.0 in all of the five imputed dataset). Further, based on number
of outcomes (62 deaths), combination of the following six predictors were considered to be rea-
sonably fitted to the final multivariable logistic regression model: eGFR>7 mL/min per 1.73
m2, serum albumin<3.5 g/dL, calcium>8.5 mg/dL, modified CCI1 points (higher risk for3
points), performance status1 points (higher risk for 3–4 points), and ESA non-use (Table 3).
For the analysis population, calculations showed an area under the ROC curve of 0.829.
Validation
Predictive discrimination of 1-year mortality was good, with an area under ROC curve of 0.831
(95% confidence interval, 0.789–0.892). The predicted risks of approximately 20% of the appar-
ent model were overestimated, and the predicted risks of>40% were underestimated (Fig 2).
The bias-corrected estimate was slightly nonlinear but only slightly improved compared to the
apparent calibration. The 90 percentile of absolute error in predicted mortality risks between
the bootstrap and original model is 0.013, which suggests only a small degree of bias from
over-fitting in the original model.
Development of Risk Score
Table 4 shows the score chart derived from the final logistic regression model (Table 3) that
can be used as a risk score. A median overall risk score of six (range: 0–12) was obtained for
each patient in the study population. Fig 3 shows predicted mortality risks and observed pro-
portions for the ranges of total scores. Some discrepancies between predicted risk and observed
proportion were observed (Table 5).
Discussion
In this multicenter cohort study, we developed a simple risk score using parameters from blood
examinations obtained in routine clinical evaluations to predict 1-year mortality in stage 5
CKD patients who were starting HD. This score might provide a personalized assessment of
mortality risk of CKD patients under predialysis nephrology care and help nephrologists make
a shared decision with patients and their families regarding the initiation of HD.
Our risk score to predict 1-year mortality is composed of the following six items available at
initiation of HD: high eGFR level (>7 mL/min per 1.73 m2), low serum albumin levels, high
calcium levels, high modified CCI, low performance status, and no use of ESA.
One-year Mortality Score for Patients Initiating HD
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These items have a number of clinical implications or similarities to previous studies. First,
despite the exclusion of eGFR patients with>10 mL/min per 1.73 m2, mortality prediction of
high eGFR is in good agreement with a previous study showing that of patients who started
HD, those with eGFR of 8–10 mL/min per 1.73 m2 had higher mortality than those with eGFR
of 4–6 mL/min per 1.73 m2 [3]. However, whether the initiation of HD when eGFR levels are
high directly causes earlier death is still controversial. Of note, comorbidity, which causes











Choice with further discussion
based on clinical relevance
Age, year
Female gender
Body mass index >18 X X X X X Chosen
Primary renal disease X X X X
eGFR>7 mL/min per 1.73
m2
X X X X X Chosen
Urea nitrogen, mg/dL
Haemoglobin, g/dL
Serum albumin<3.5 g/dL X X X X X Chosen
Serum potassium, mEq/L X X
Serum calcium>8.5 mg/
dL





X X X X
Modiﬁed Charlson
Comorbidity Indexa
X X X X X Chosen
Performance status X X X X X Chosen
Fatigue
Edema













ESA use X X X X X Chosen
Predictors listed in this table were entered to logistic regression model with backward elimination procedure. X indicates predictors retained after backward
elimination procedure in each of the ﬁve imputed dataset. Predictors which retained all of the ﬁve imputed dataset were considered as candidate
predictors of ﬁnal prediction model. After further discussion based on clinical relevance, six predictors were chosen as the ﬁnal prediction model.
eGFR, estimated glomerular ﬁltration rate; CNS, central nervous system; ESA, erythropoiesis-stimulating agent
aItems related to diabetes and renal disease were excluded from the original Charlson Comorbidity Index in the present study.
doi:10.1371/journal.pone.0129180.t002
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decompensated symptoms related to the renal failure even though eGFR is relatively preserved,
might exacerbate poor mortality.
Second, mortality prediction related to high modified CCI, hypoalbuminemia, and low per-
formance status is also compatible with previous reports [5, 18, 19]. Hypoalbuminemia might
indicate malnutrition, nephrotic, or chronic inflammatory state and can be partially modified
by medical care. Predialysis management for nutrition and proteinuria might therefore im-
prove survival after initiation of HD.
Table 3. Multivariable predictors of 1-year mortality and associated risk scoring system.
Variables Adjusted odds ratio 95% conﬁdence interval β-coefﬁcienta Risk scoreb
eGFR>7 mL/min per 1.73 m2 2.05 1.13–3.74 0.66 1
Serum albumin<3.5 g/dL 2.33 0.96–5.63 0.77 1
Serum calcium>8.5 mg/dL 2.80 1.41–5.59 0.94 2
Modiﬁed Charlson Comorbidity Indexc (vs. 0)
1–2 3.59 1.57–8.20 1.17 2
3 6.74 2.57–17.6 1.74 3
Performance status (vs. 0)
1–2 2.03 0.45–9.13 0.65 1
3–4 6.75 1.51–30.1 1.74 3
ESA non-use 3.29 1.67–6.45 1.09 2
eGFR, estimated glomerular ﬁltration rate; ESA, erythropoiesis-stimulating agent
aOriginal β-coefﬁcients multiplied by heuristic shrinkage factor to improve predictions for future patients.
bScores assigned by dividing the shrunken β-coefﬁcients by 0.568 and rounding to nearest integer.
cItems related to diabetes and renal disease were excluded from the original Charlson Comorbidity Index in the present study.
doi:10.1371/journal.pone.0129180.t003
Fig 2. Agreement between the predicted mortality risks and the observed proportions. The short-
dashed line (“Apparent”) indicates the agreement between predicted mortality risks and observed proportions
of the original model. The sold line (“Bias-corrected”) indicates the agreement between predicted mortality
risks and observed proportions of the bootstrap model.
doi:10.1371/journal.pone.0129180.g002
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Third, accurate mortality prediction based on elevated serum calcium levels is consistent
with previous findings of mortality risk related to abnormally elevated calcium levels among
CKD patients and the incidence HD [20–25]. Increased serum calcium levels are generally
caused by certain drugs, presence of malignancies or immobility. It might be speculated that
one of the reasons of higher serum calcium levels in predialysis CKD patients is to use drugs
such as calcium-based phosphate binder, vitamin D or thiazide as it was independent of serum
albumin level and lower performance status as proxy for immobility. For example, coronary
calcification induced by calcium-based phosphate binders occurred more than that by sevela-
mer in CKD patients [26].
Fourth, mortality prediction with no use of an ESA before initiation of HD is consistent with
previous reports [27, 28]. However, the beneficial effect of an ESA for CKD before the initiation
of HD is controversial. In addition, the use of an ESA in the present study might indicate the
provision of high quality management by nephrologists, which might be partially supported by
higher proportion of the patients receiving an ESA than those in the previous study [29].
Table 4. Score chart to predict 1-year mortality risk.
Points 0 1 2 3
eGFR>7 mL/min per 1.73 m2, yes No Yes
Serum albumin<3.5 g/dL, yes No Yes
Serum calcium>8.5 mg/dL, yes No Yes
Modiﬁed Charlson Comorbidity Index, pointsa 0 1–2 3
Performance status, points 0 1–2 3–4
ESA non-use, yes No Yes
Points correspond to each predictor value and are added to give a score.
eGFR, estimated glomerular ﬁltration rate; ESA, erythropoiesis-stimulating agent
aItems related to diabetes and renal disease were excluded from the original Charlson Comorbidity Index in
the present study.
doi:10.1371/journal.pone.0129180.t004
Fig 3. Predicted mortality risks and observed proportions for ranges of total scores. Prognostic score
calculated form the following six items well predicts 1-year mortality for patients initiating haemodialysis: high
eGFR level (>7 mL/min per 1.73 m2), low serum albumin levels, high calcium levels, high modified Charlson
Comorbidity Index, low performance status, and no use of ESA. The modified Charlson Comorbidity Index
was excluded items related to diabetes and renal disease from the original Charlson Comorbidity Index in the
present study.
doi:10.1371/journal.pone.0129180.g003
One-year Mortality Score for Patients Initiating HD
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Our risk score differs from previous scores with respect to target population and simplicity
as well as availability of parameters in a routine nephrology care setting. For example, the prog-
nostic score developed by Couchoud et al. was only applicable to elderly patients [1], whereas
our score doesn’t include age. It may be counterintuitive that age was not associated with
1-year mortality. However, it is possible that effect of age on mortality was lessened by adjust-
ment of performance status and comorbidity, as both are associated with aging. Regarding rou-
tine nephrology care settings, they included irrelevant patients with unplanned initiation of
HD who have higher mortality than those with planned initiation of HD [30], and whether or
not their patients received medical care by the nephrologists is unknown. In contrast, our risk
score was developed from patients who received predialysis nephrology care and whose eGFR
was then 10 mL/min per 1.73 m2 in an out-patient setting. Our score might therefore be more
accurate than the previous scores for nephrologists when referring to personalized mortality
risks to decide whether to initiate HD. The prognostic score developed by van Diepen et al. was
also restricted to patients with diabetic nephropathy with a complicated score calculation re-
quiring computer assistance [5]. Chua et al. developed a 5-item prognostic tool with simple in-
teger scores; however, this tool is difficult to use in routine settings due to the requirement of
echocardiography measurement [31]. In contrast to these previous studies, our risk score is ap-
plicable for CKD patients regardless of age and underlying disease and composed of simple in-
teger scores available in daily nephrology practice settings.
The strength of this study is that the 6-item risk score for predicting 1-year mortality was de-
veloped using clinical data available immediately before the initiation of HD frommulticenter
nephrology institutions. As mortality tends to be relatively high one year after starting HD, this
integer risk score might be useful for estimating prognosis, identifying high-risk patients, and
making care plans. For example, when bedridden CKD patients with hemiplegia and peripheral
vascular disease exhibit a low level of serum albumin and a high level of calcium, predicted
1-year mortality is>25% according to our risk score. The nephrologist would therefore be able
to discuss HD initiation based on this predicted mortality with the patient and their family.
However, several limitations also warrant attention in the present study. First, CKD patients
who started HD with an eGFR>10 mL/min per 1.73 m2 were excluded from this study. This
might explain why emergent complications related to CKD, such as pulmonary edema, were
not retained in the risk scores. Second, as our risk score was only validated internally, external
validation should also be conducted. Third, 1-year mortality in the present population was
lower than that reported in the Japanese registry (15.9%) [3]. This lower mortality might be ex-
plained by the exclusion of patients with eGFR>10 mL/min per 1.73 m2 at initiation of HD, as
a higher level of eGFR at the initiation of HD is associated with mortality [4, 18, 19, 32]. In ad-
dition, patients enrolled in the present study received predialysis nephrology care at least once,
which has been related to improved survival after the initiation of HD [29, 33].
Table 5. Predictedmortality risks and observed proportions for ranges of total scores.
Total Score Predicted mortality risk Observed proportion
% (n/N)a
0–4 2.5% 1.7% (4/235)
5–6 5.5% 6.6% (15/228)
7–8 15.2% 16.6% (26/157)
9–12 28.9% 25.0% (17/68)
aNumber of patients experiencing 1-year mortality/total number of patients in each risk category.
doi:10.1371/journal.pone.0129180.t005
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In conclusion, we developed and validated a simple risk score in CKD patients receiving
predialysis nephrology care to predict 1-year mortality after the initiation of HD. This score
might help nephrologists make personalized assessments for risk of mortality and facilitate
making a shared decision with patients and families regarding the initiation of HD.
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